NEW YORK (AP) — U.S. stocks fell Thursday, while oil prices rose with worries about a potential conflict between the United States and Iran. The S&P 500 slipped 0.3% for its first loss in four days. The Dow Jones Industrial Average dropped 267 points, or 0.5%, and the Nasdaq composite slipped 0.3%. Booking Holdings dropped 6.1% for one of the market’s sharper losses, even though the company behind the Booking.com, Priceline and OpenTable brands reported a profit for the latest quarter that edged past a ...

NEW DELHI, Feb 19 (Reuters) - OpenAI will become the first customer of India's ‌Tata Consultancy Services' data centre business, ‌beginning with 100 megawatts of capacity, part of the ​global AI infrastructure initiative Stargate, the companies said. Stargate is a $500 billion multi-year initiative to build AI data centres for training and inference, ‌backed by major ⁠investors. The deal is a major boost for TCS, which in a ⁠strategic shift last year disclosed plans to invest up to $7 billion in a 1 gi ...

Pepperstone Group's Chris Weston says investors "are seeing a more sort of universal earnings breadth and that means a stock picker's market." He tells Bloomberg Television that people are also finding growth and opportunity outside of the Magnificent Seven group. ...

Toru Yoshimura, Senior Executive Officer at Kirin, discusses the company's business strategy and expansion plans for its health science business. He speaks with Shery Ahn and Avril Hong on Bloomberg: The Asia Trade. ...

Definium Therapeutics, Inc. (NASDAQ:DFTX) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III The third stock on our list of most promising stocks is Definium Therapeutics, Inc. (NASDAQ:DFTX). TheFly reported on January 30 that Jefferies initiated coverage of DFTX with a Buy rating and a $30 price target. The firm highlighted that a single dose of DT120, which ...

Cybin D/B/A Helus Pharma (NASDAQ:HELP) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers The seventh stock on our list of most promising stocks is Cybin D/B/A Helus Pharma (NASDAQ:HELP). TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also highlighted significant upside potential. The firm has identifi ...

GH Research PLC (NASDAQ:GHRS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. RBC Capital Cite GH Research PLC's (GHRS) Long-Term Sales Potential Following Psychedelics Symposium GH Research PLC (NASDAQ:GHRS) is placed sixth on our list. TheFly reported that on January 23, RBC Capital raised its price target on GHRS to $40 from $33 and maintained an Outperform rating. RBC stated that it was growing more hopeful about GHRS's long-term sales potential, particularly GH001, follow ...

Edison International delivered a surge in 2025 earnings and rolled out new core EPS guidance for 2026 and 2027, reinforcing its outlook for 5–7% annual earnings growth through the end of the decade. The California-based utility holding company reported fourth-quarter 2025 GAAP earnings of $4.80 per share, up from $0.88 per share a year earlier, while core earnings came in at $1.86 per share, compared with $1.05 per share in the same period of 2024. Full-year GAAP earnings rose to $11.58 per share from $3. ...

VivoPower International executive chairman Kevin Chin talked with Proactive about the company’s $30M strategic PIPE investment and its accelerating AI data centre strategy. Chin described the funding as “strategic capital” from long-term institutional investors and sovereign family offices based in the UAE and Saudi Arabia. He explained that the private investment in public equity (PIPE) structure brings sophisticated investors with experience in AI data centre businesses, adding not only capital but also ...

Walking into Target isn't what it used to be. Years back, my friends and I used to joke that it was impossible to make it through a Target shopping trip without spending a minimum of $100. Now, it's gotten all too easy to avoid impulse buys — namely because a lot of Target stores have simply lost their charm. It's a shame, too. Not long ago, fans of the big-box giant were affectionately calling the store "Tarzhay" due to its appealing range of modestly priced higher-end inventory. Now, a lot of the pr ...